| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | 米田 浩人
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 2. | 軒原 浩
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 三橋 惇志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | 尾崎 領彦 ([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 5. | (英) Yabuki Yohei (日) 矢葺 洋平 (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 6. | 荻野 広和 ([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | 大塚 憲司
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | 西岡 安彦 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) This is the first study to report the correlation between irAEs and therapeutic effects in patients with MPM. Because the presence of irAEs may be associated with a favorable clinical outcome, early detection and appropriate management of irAEs will increase the therapeutic benefits to patients. (日) Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108).
| [継承] |
| ○キーワード (推奨): | 1. | (英) Aged (日) (読)
| [継承] |
| 2. | (英) Aged, 80 and over (日) (読)
| [継承] |
| 3. | (英) Antineoplastic Agents, Immunological (日) (読)
| [継承] |
| 4. | 女性 (female)
| [継承] |
| 5. | (英) Humans (日) (読)
| [継承] |
| 6. | (英) Immune System Diseases (日) (読)
| [継承] |
| 7. | (英) Male (日) (読)
| [継承] |
| 8. | (英) Mesothelioma, Malignant (日) (読)
| [継承] |
| 9. | (英) Middle Aged (日) (読)
| [継承] |
| 10. | (英) Nivolumab (日) (読)
| [継承] |
| 11. | (英) Retrospective Studies (日) (読)
| [継承] |
| 12. | (英) Survival Analysis (日) (読)
| [継承] |
| 13. | (英) Treatment Outcome (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | BMC Pulmonary Medicine ([BioMed Central Ltd.])
(eISSN: 1471-2466)
| ○ISSN (任意): | □ | 1471-2466
ISSN: 1471-2466
(eISSN: 1471-2466) Title: BMC pulmonary medicineTitle(ISO): BMC Pulm MedPublisher: BioMed Central (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 21
| [継承] |
| ○号 (必須): | □ | 1
| [継承] |
| ○頁 (必須): | □ |
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2021年 11月 15日 (令和 3年 11月 15日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1186/s12890-021-01746-6 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 34781910 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) PublicationType: Journal Article (日)
| [継承] |